EarningsQ2 2026 Earnings Report
DGWPF Q2 2026 EPS Results
Actual EPS$1.77
Consensus EPS$1.77
Beat/MissMet expectations
One Year Ago EPS$0.68
DGWPF Q2 2026 Revenue Results
Actual Revenue$949.36M
Expected Revenue$931.72M
Beat/MissBeat by +$17.64M
YoY Revenue Growth+8.63%
Earnings Announcement Details
QuarterQ2 2026
Date07/30/2026
TimeBefore Open
Conference CallThursday, July 30, 2026
DGWPF Upcoming Earnings
Draegerwerk AG & Co. KGaA's next earnings date is estimated for October 29, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a clearly improved operational and financial performance: strong net sales growth, materially higher EBIT and margins, improved cash flows and a stronger balance sheet. Safety division delivered robust top-line and margin expansion, and Medical shows improving trends with Q2 returning to positive EBIT despite order intake being affected by a prior-year large Mexico order. Key headwinds are rising personnel and freight costs, APAC softness in places, and some remaining working capital increase. One-off customs refunds materially aided margins but carry timing/amount uncertainty. On balance, positive operational momentum and upgraded guidance outweigh the challenges.Company Guidance
Order Intake and Net Sales Growth
Order intake of around EUR 1.75 billion was slightly above prior year levels; net sales increased by more than EUR 90 million to ~EUR 1.6 billion, +7.7% in H1 and +8.5% in Q2 (currency-adjusted).
Significant EBIT Improvement
Group EBIT more than tripled to ~EUR 64 million in H1 (EBIT margin 4.0% vs 1.3% prior year). Q2 EBIT more than doubled to ~EUR 46 million (EBIT margin 5.4% vs 2.6% prior year).
Gross Margin Expansion
Group gross margin improved by 1.7 percentage points to 46.5% in H1; Medical gross margin expanded by 2.1 pp to 44.6%; Safety gross margin increased by ~1 pp in H1.
Safety Division Outperformance
Safety order intake +9.5% in H1 and +19.8% in Q2; Safety net sales +7.8% in H1; Safety EBIT rose from ~EUR 54 million to ~EUR 78 million, lifting the EBIT margin from ~8% to ~11% (Q2 margin 11.3%).
Medical Division Profitability Momentum
Medical net sales rose ~7.6% to ~EUR 898 million in H1 (Q2 +9.7%); Medical EBIT materially improved from -EUR 33.7 million to -EUR 14.3 million in H1 and returned to positive territory in Q2 at EUR 4.3 million (Q2 margin 0.9%).
Cash Flow and Balance Sheet Strengthening
Operating cash flow improved by ~EUR 43 million to ~EUR 60 million; free cash flow rose to ~EUR 16 million from -EUR 42 million (improvement of ~EUR 58 million); net financial debt reduced by ~EUR 79 million to ~EUR 190 million; net debt/EBITDA ~0.5; equity ratio ~52%.
Upgraded 2026 Guidance
Company reaffirmed net sales growth guidance of 2%–6% (currency-adjusted) and raised EBIT margin guidance to 6%–8% following customs refunds and strong operating performance (previous lower end had been raised to 5.5%).
One-off Positive Customs Refunds
Customs refunds provided a notable earnings tailwind: EUR 7.8 million recognized in Q2 COGS, ~EUR 14.2 million received after the half-year (to be recognized in Q3), and a potential further EUR 7–9 million possible (timing/amount uncertain).
DGWPF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed